KLRK1 and lung carcinoma: Similar results were obtained when the expression of both HDAC1 or HDAC2 was inhibited, suggesting that suppressing HDAC1 and HDAC2 expression both genetically and pharmacologically leads to activation of NKG2D ligands and facilitate NK cell-mediated anti-tumor effects in lung cancer (21).